グローバルにおける統合失調症（Schizophrenia）治療薬市場及びパイプライン分析...市場調査レポートについてご紹介

1. Schizophrenia Drug Market Overview
1.1 Market Overview
1.2 Clinical Insight

2. Schizophrenia Drugs Clinical Pipeline by Phase & Country
2.1 Unknown Phase
2.2 Research
2.3 Preclinical
2.4 Clinical
2.5 Phase I
2.6 Phase I/II
2.7 Phase II
2.8 Phase II/III
2.9 Phase III
2.10 Preregistration

3. Marketed Schizophrenia Drugs Clinical Insight & Patent Analysis

4. Suspended & Discontinued Schizophrenia Drug Profile
4.1 No Development Reported
4.2 Discontinued
4.3 Suspended

5. Competitive Landscape
5.1 Abbott Laboratories
5.2 Addex Pharmaceuticals
5.3 Astellas Pharma
5.4 Dainippon Sumitomo Pharma
5.5 Eli Lilly
5.6 GlaxoSmithKline
5.7 Johnson & Johnson
5.8 Merck
5.9 Pfizer
5.10 Roche
5.11 Sanofi

Figure 1-1: Schizophrenia Drug Market (US$ Billion), 2013-2020
Figure 1-2: Schizophrenia Treatment Process in Future
Figure 1-3: Schizophrenia Drug Clinical Pipeline by Phase (%), 2014
Figure 1-4: Schizophrenia Drug Clinical Pipeline by Phase (Number), 2014
Figure 1-5: No Development Reported in Schizophrenia Drug Clinical Pipeline by Phase (%), 2014
Figure 1-6: No Development Reported in Schizophrenia Drug Clinical Pipeline by Phase (Number), 2014
Figure 1-7: Discontinued Schizophrenia Drug Clinical Pipeline by Phase (%), 2014
Figure 1-8: Discontinued Schizophrenia Drug Clinical Pipeline by Phase (Number), 2014
Figure 1-9: Suspended Schizophrenia Drug Clinical Pipeline by Phase (%), 2014
Figure 1-10: Suspended Schizophrenia Drug Clinical Pipeline by Phase (Number), 2014

List of Tables
Following Information For Each Drug Profile in Covered in More than 200 Tables in Report:
• Drug Profile Overview
• Active Indication
• Phase of Development
• Country for Clinical Trial
• Owner / Originator/ Licensee/Collaborator
• Administrative Route
• Drug Class